Drug Trial Radar · NCT05872347
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Sep 19, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
Conditions
- Breast Cancer Brain Metastases
Interventions
SPH4336 TabletsDrug
SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion; Exemestane:Administered by oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intracranial Objective response rate(iORR)Time frame: Approximately 3 years
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Recruiting
Chongqing University Three Gorges Hospital
Chongqing, China · Recruiting
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute
Nanning, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Xi'An International Medical Cancer Hospital
Xi'an, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Anhui provincial hospital
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Affiliated Cancer Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Liuzhou people's Hospital
Liuzhou, Guangxi, China · Recruiting
Anyang Cancer Hospital
Anyang, He'nan, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, He'nan, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China · Recruiting
The second people's hospital of neijiang
Neijiang, Sichuan, China · Recruiting
Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Recruiting
Zhejiang cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.